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Aims/hypothesis—The ability to measure insulin sensitivity across the phenotypic spectrum of 
diabetes may contribute to a more accurate characterisation of diabetes type. Our goal was to 
develop and validate an insulin sensitivity (IS) score using the euglycaemic–hyperinsulinaemic 
clamp in a subset (n=85) of 12– to 19-year-old youths with diabetes participating in the SEARCH 
study in Colorado, USA.
Methods—Youths with a diagnosis of type 1 (n=60) or type 2 diabetes (n=25) underwent a 3 h 
clamp to measure glucose disposal rate (GDR, mg kg−1 min−1). Demographic (age, sex, race), 
clinical (BMI, waist, Tanner stage) and metabolic characteristics (HbA1c, lipids, blood pressure, 
urine albumin:creatinine) were used to estimate logeIS score via stepwise linear regression on a 
model- development set (n=53). Estimated IS score was evaluated for reproducibility on two 
validation sets: youths with diabetes (n=33) and healthy control youths (n=22).
Results—The best model included waist, triacylglycerol (TG) and HbA1c levels (R2=0.74). 
Diabetes type did not enter the model and there were no significant interactions between diabetes 
type and other predictors. Estimated IS score correlated well (r=0.65, p<0.0001; r=0.62, p=0.002) 
with GDR on the two validation sets. Based on this analysis, we propose the following formula to 
estimate insulin sensitivity in youths with diabetes: logeIS = 4.64725 – 0.02032 (waist, cm) – 
0.09779 (HbA1c, %) – 0.00235 (TG, mg/dl;to convert TG values from mmol/l to mg/dl, divide by 
0.0113).
Conclusions/interpretation—Insulin sensitivity can be estimated in adolescents with diabetes 
using routinely collected measures. This score can be applied to epidemiological studies of youths 
with diabetes to characterise relationships between dimensions of diabetes type.
Keywords
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Introduction
Diabetes in youth is caused by a spectrum of varying degrees of beta cell dysfunction and 
insulin insensitivity [1]. There is good evidence that one variant of diabetes, type 1A, is 
mediated by immune processes. On the other hand, insulin insensitivity relative to the 
body’s capacity to secrete insulin is the hallmark of type 2 diabetes. However, reduced 
insulin sensitivity (IS) relative to healthy controls has also been documented in adults [2] 
and adolescents [3] with autoimmune diabetes and has recently been proposed as the 
common basis for both major diabetes types [4]. The ability to measure insulin sensitivity 
consistently across the phenotypic spectrum of diabetes is therefore important as it may 
contribute to a more accurate characterisation of diabetes type.
While it is possible to measure insulin sensitivity rigorously in adolescents with diabetes 
using euglycaemic–hyperinsulinaemic clamp techniques [3, 5], these are labour- and time-
intensive and not useful for large epidemiological studies. At the same time, surrogate 
estimates of insulin sensitivity, HOMA-insulin resistance (HOMA-IR) or the quantitative 
insulin sensitivity check index (QUICKI) [6], cannot be used in insulin-treated patients and 
may be inaccurate in youths with type 1 diabetes, as they assume preserved insulin and C-
peptide secretion and normal glucose levels [7]. Therefore, the development of estimates of 
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insulin sensitivity that do not rely on preserved insulin secretion and can be used equally 
reliably in insulin- and non-insulin-treated patients is fundamental to progress in the study of 
insulin sensitivity in youths with diabetes.
The SEARCH for Diabetes in Youth study undertook a comprehensive evaluation of 
childhood diabetes [8]. SEARCH has established incidence and prevalence estimates for 
youths with diabetes by race/ethnicity, age and diabetes type and well-characterised cohorts 
of youths with diabetes who can participate in future studies [9]. We are extending this effort 
by developing and validating a surrogate marker of insulin sensitivity, the IS score, using the 
euglycaemic- hyperinsulinaemic clamp in a subset of SEARCH participants from Colorado, 
USA. As an example of potential applications of the IS score in large epidemiological 
studies, we modelled the relationship between residual insulin secretion, assessed by fasting 
C-peptide levels, and insulin sensitivity, based on the estimated IS score, in the SEARCH 
population of youths who completed a study visit (n=2,417).
Methods
Overview of SEARCH for Diabetes in Youth
SEARCH is an ongoing US multicentre study that conducts population-based ascertainment 
of cases of diabetes in youths less than 20 years of age [9]. Self-reported race and ethnicity 
are collected through an initial survey using the 2000 US Census questions [10]. Eligible 
youths are invited to a study visit. Fasting blood samples are drawn for measurement of 
HbA1c, C-peptide and lipids, and a urine sample is collected [8, 11]. Specimens are shipped 
within 24 h to the central laboratory (Northwest Lipid Metabolism and Diabetes Research 
Laboratories, Seattle, WA, USA). Samples are also analysed for glutamic acid 
decarboxylase- 65 (GAD65) and insulinoma-associated-2 (IA2) diabetes autoantibodies 
(DA) using standardised protocols developed by the National Institute of Diabetes and 
Digestive and Kidney Diseases (NIDDK) consortia. The units are termed digestive and 
kidney units (DK units)/ml. The cutoff values for positivity/negativity are 33 DK units/ml 
for GAD65 and 5 DK units/ml for IA2 [11]. DA status is classified as positive when either 
GAD65 or IA2 is positive, and negative when both antibodies have negative titres. A brief 
physical examination includes height, weight and waist circumference, an evaluation for 
acanthosis nigricans, measurement of systolic and diastolic blood pressure, and self-assessed 
Tanner stage [8, 12].
Euglycaemic–hyperinsulinaemic clamp study
Youths aged 12–19 years with a clinical diagnosis of type 1 or type 2 diabetes [13] and who 
participated in SEARCH in Colorado, USA, were recruited into a euglycaemic–
hyperinsulinaemic clamp study. There were 255 eligible youths, 208 with a diagnosis of type 
1 and 47 with type 2 diabetes, which reflects the typical distribution of diabetes type in 
Colorado youths [9]. The recruitment target of 80 participants was estimated to provide 80% 
power to identify individual factors that explain at least 10% of the variance in glucose 
disposal rate (GDR) and combinations of factors that explain at least 70% of the variance in 
GDR. By the completion of the study we were able to recruit a total of 85 participants, 60 
with type 1 (30% of those eligible) and 25 with type 2 diabetes (53% of those eligible).
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Eligibility criteria included: age 12–19 years, HbA1c <12%, serum creatinine <114 μmol/l 
and a normal haemoglobin and haematocrit. Participants were ineligible if they were unable 
to discontinue metformin prior to clamp, if they had recently used medicines known to affect 
insulin sensitivity or if they had an episode of diabetic ketoacidosis or severe illness within 
the last 60 days. Participants with diabetes were group-matched by type for age, sex and 
Tanner stage.
A screening visit was conducted 2 weeks prior to the clamp study [3]. Participants had a 
screening blood sample taken for HbA1c, haemoglobin and haematocrit and a brief medical 
history. Participants were instructed not to change their dietary and physical activity patterns 
during the course of the study and were provided with a 3 day fixed- macronutrient weight-
maintenance diet (55% carbohydrates, 30% fat, 15% protein content). Participants were 
asked to monitor blood glucose levels at least four times a day and were called daily to 
check on blood glucose. Individuals taking metformin had their medication withdrawn 3 
days prior to the admission for the euglycaemic clamp.
Participants were admitted to the Pediatric Clinical Research Center (Aurora, CO, USA) in 
the afternoon. A physical examination was conducted by a paediatric endocrinologist. All 
data-collection forms and measurements were based on SEARCH protocols. Long-acting 
insulin and insulin pumps were disconnected. At 20:00 hours, two intravenous catheters 
were inserted: one was placed in a vein in the antecubital region for administration of insulin 
and glucose, and the second was placed on the contralateral hand for blood sampling. Blood 
glucose was monitored and insulin infusion was regulated according to a standardised 
protocol to stabilise blood glucose levels at 5.5–8.3 mmol/l overnight and at 4.9–6.1 mmol/l 
between 06:00 hours and 09:00 hours. A fasting blood sample and a urine sample were 
obtained immediately before the initiation of the clamp study.
The euglycaemic–hyperinsulinaemic clamp was started at 09:00 hours, with a continuous 
infusion of regular insulin at a constant rate of 80 mU m−2 min−1 for a total of 180 min. 
During the clamp, the plasma glucose was maintained at 5.5 mmol/l [14, 15] by concomitant 
intravenous infusion of 20% dextrose, on the basis of plasma glucose determinations every 5 
min from a heated hand vein, using a Yellow Springs Instruments (Mountain View, CA, 
USA) glucose analyser. GDR (M value) was calculated as the mean glucose infusion 
required to maintain euglycaemia in mg kg−1 min−1, during the final 30 min of clamp. The 
study was approved by the relevant institutional review boards and was carried out in 
accordance with the Declaration of Helsinki revised in 2000. All study participants provided 
informed consent.
Statistical analysis
Development and validation of IS score—Multiple linear regression was used to 
develop a surrogate measure of insulin sensitivity. The goal was to develop the most 
explanatory set of variables, i.e. the model explaining the largest amount of variability in the 
outcome (GDR) in the combined sample of youths with both clinical phenotypes of diabetes.
We used a model-development set of 53 participants (39 with type 1 and 14 with type 2 
diabetes) and a validation sample of 32 participants (21 with type 1 and 11 with type 2 
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diabetes) to assess the reliability of the model through cross-validation. The splitting 
proportion was based on recommendations that the relative size of the model-development 
sample be increased when sample sizes are relatively small [16]. Block randomisation was 
used to assign individuals to the model-development or validation sample within strata 
defined by group (type 1, type 2 diabetes), age group (12–15 and 16–19 years) and body 
mass index percentile (≥85th and <85th). We also included an additional sample of 22 non-
diabetic healthy control youths, aged 12–19 years, who were part of a different study using 
the same clamp protocol, to serve as a secondary validation sample.
Although all values of the GDR were positive, some were close to zero and a linear 
regression model of explanatory variables predicting the value of GDR led to some negative 
predictions. Therefore, we used a natural log transformation of GDR in the models, causing 
the antilogs of the predicted values to be positive. We regressed the logeGDR value on 
demographic characteristics (age, sex, race/ethnicity) and clinical and metabolic markers 
(Tanner stage, waist circumference, BMI, lipids [total cholesterol, LDL-C, HDL-C, 
triacylglycerol {TG}], blood pressure, HbA1c, fasting C-peptide, urine albumin:creatinine 
ratio) measured during the clamp study and available for the larger SEARCH population. To 
arrive at a regression-based score that best predicts insulin sensitivity we used stepwise 
linear regression and relied on the Mallows’ Cp statistic and adjusted R2 to choose the best 
number of predictors to be included in the final model. The significance level for entry and 
removal of variables was pre-specified at p=0.05. Indicator variables were created to identify 
group membership (diabetes type) and interaction terms between the indicator and candidate 
variables were constructed to explore different regression relationships by diabetes type.
We examined whether our best-fitting model met all the assumptions of linear regression. 
Both the Shapiro-Wilk test (p=0.53) and Kolmogorov-Smirnov test (p>0.15) indicated that 
the residuals did not deviate significantly from a normal distribution. A plot of residuals 
against the predicted values of the outcome variable (logeIS) found no evidence that the 
variance of the residuals was changing across the range of predicted values. Finally, the best-
fitting model was cross-validated by regressing measured GDR vs predicted IS in the two 
validation sets (youths with diabetes and healthy control youths).
Modelling—the relationship between residual insulin secretion and insulin sensitivity in the 
entire SEARCH population IS score was used to model the relationship between residual 
insulin secretion, assessed by fasting C-peptide levels, and insulin sensitivity, estimated 
according to back- transformed IS values, among 2,417 SEARCH study participants newly 
diagnosed with diabetes in 2002–2006. The relationship of fasting C-peptide and the IS 
score was explored via orthogonal regression. This method minimises the orthogonal sum of 
squared errors and is appropriate when error in the x-axis variable is present and/or the 
determination of which variable is independent is not possible. A two-piece linear spline 
modelled the data most appropriately, and the parameters of the final model were arrived at 
using an automated parameter estimation technique in which 5 million initial parameter 
estimates were compared. Separate analyses were conducted to determine less constrained 
relationships in fasting C-peptide by antibody status and IS score via smoothed spline 
regression (SAS proc transreg; sm60 smoothing option).
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A total of 85 adolescents with diabetes participated in the clamp study. Compared with the 
SEARCH population of patients incident in 2002–2006, participants in the clamp study were 
older (15.4 vs 11.7 years, p<0.001) and had longer diabetes duration (63.5 vs 10.2 months, 
p<0.001). Reflecting the racial/ethnic composition of the Colorado population, participants 
with diabetes in the clamp study were non-Hispanic white (70%), Hispanic (25%) and 
African-American (5%). Nevertheless, the sample participating in the clamp study was 
otherwise typical of the larger population of youths with type 1 or type 2 diabetes 
participating in SEARCH [12, 17, 18].
Characteristics of youths with type 1, type 2 or no diabetes (i.e. healthy controls) who had a 
clamp measurement are presented in Table 1. As youths with type 1 and type 2 diabetes 
were group-matched for age, sex and Tanner stage, there were no significant differences in 
these characteristics by diabetes type. As expected, compared with youths with type 1 
diabetes, youths with type 2 diabetes were more likely to have: a minority racial/ethnic 
background; significantly more obesity-related traits; higher fasting C-peptide levels; and 
lower GDR.
Table 2 presents the best model and the most practical model resulting from stepwise linear 
regression analyses for prediction of logeGDR on the model-development sample (n=53). 
The best model, allowing any of the variables in Table 1 to enter, included waist 
circumference, TG and HbA1c levels (adjusted model R2=0.74). Of note, most of the 
variance in logeGDR was explained by waist circumference alone, and removal of TG and 
HbA1c resulted in a similar model, i.e. the most practical model (R2=0.60). Although GDR 
was substantially lower in youths with type 2 vs type 1 diabetes (4.3 vs 8.5 mg kg−1 min−1, 
p<0.0001), diabetes type was no longer significantly associated with GDR once waist 
circumference was included, and did not enter the final model. In addition, similar models 
were obtained in analyses stratified according to clinical diabetes type, suggesting that the 
different proportions of youths with type 1 and type 2 diabetes included in these analyses did 
not influence the selected model. Finally, there were no significant interactions between 
clinical diabetes type and other predictors of GDR. Older age (p=0.002) and higher body 
weight (p<0.0001), BMI (p<0.0001) and total cholesterol (p=0.02) were each associated 
with reduced GDR, but did not enter the model. As 80% of participants in this sample were 
Tanner stage 3 or higher, pubertal development was only weakly associated with GDR 
(p=0.05) and did not enter the model.
Based on the best model (Table 2), the estimated IS score can be calculated as follows: 
logeIS = 4.64725–0.02032 (waist, cm) – 0.09779 (HbA1c, %) – 0.00235 (TG, mg/dl; to 
convert TG values from mmol/l to mg/dl, divide by 0.0113).
Based on the most practical model (Table 2), the estimated IS score can be calculated as 
follows: logeIS = 3.7339 – 0.02155(waist, cm)
Figure 1 presents the correlation between observed GDR and predicted IS score using the 
best model on the two validation samples: youths with diabetes (n=32; Fig. 1a); and healthy 
youths (n=22; Fig. 1b). For both validation sets, the correlation was good (Pearson 
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correlation coefficient r=0.65, p<0.0001 for youths with diabetes, similar in youths with type 
1 and type 2 diabetes; r=0.62, p=0.002 for control youths). In addition, the mean difference 
between measured and predicted IS was not significant (p>0.05). In sensitivity analyses, 
type 1- and type 2- specific formulae were derived and then validated in the other diabetes 
type group and in controls, with very consistent results. As clamped insulin levels (type 
1,694.5±215.3 pmol/l; type 2, 743.1±236.1 pmol/l; controls, 722.3±229.2 pmol/l) did not 
differ between the groups, adjusting the glucose infusion rate for this measure did not 
change the findings.
Figure 2 presents the relationship between fasting C-peptide and predicted IS score using the 
best model on the entire sample of SEARCH participants (n=2,417). The relationship that 
best fitted the data was a two-piece linear regression spline with a knot at an IS score of 7.7 
and a fasting C-peptide level of 0.14 nmol/l. This spline had a negligible slope (Spearman 
coefficient r=0.001, p=0.9) for lower fasting C-peptide levels (n=767), with a much steeper 
negative slope (r=−0.56, p<0.001) for the fasting C-peptide levels above 0.14 nmol/l 
(n=1,650).
There was a difference in the relationship of fasting C- peptide levels to IS score by diabetes 
antibody status (Fig. 3). Smoothed spline regression curves show the fasting C-peptide 
averages across the greater part of the insulin sensitivity spectrum, stratified according to 
DA status. The most noticeable distinction was present at lower IS scores, where C-peptide 
levels appeared higher in DA- negative vs DA-positive individuals. This was due to the 
higher prevalence of DA negativity at lower IS scores. For example, in the lowest decile of 
insulin sensitivity, 75% were antibody negative. However, the inverse association between 
fasting C-peptide and IS score was present in both DA-positive (r=−0.30, p<0.0001, 
n=1,114) and DA- negative (r=−0.69, p<0.0001, n=536) participants with fasting C-peptide 
levels above 0.14 nmol/l. For higher insulin sensitivity values, these differences in fasting C- 
peptide levels by antibody status decreased to zero, and there was no significant association 
between residual insulin secretion and insulin sensitivity, regardless of DA status.
Discussion
Our study provides evidence that insulin sensitivity can be estimated in epidemiological 
studies of adolescents with diabetes across the entire diabetes spectrum, using an approach 
based on routinely collected clinical measures including waist circumference, plasma 
triacylglycerol and HbA1c levels. Using GDR derived from the euglycaemic- 
hyperinsulinaemic clamp as the accepted best marker of insulin sensitivity, the estimated IS 
score explained 74% of variance, and yielded an acceptable level of agreement on cross-
validation. Moreover, our study provides evidence that assessment of waist circumference 
may represent a simple practical alternative to estimating insulin sensitivity when fasting 
laboratory data are not available.
In individuals without diabetes, insulin secretion and sensitivity are linked through a 
negative feedback loop, whereby beta cells compensate for changes in insulin sensitivity 
through proportionate inverse changes in insulin secretion [19, 20]. However, this 
relationship is lost in the presence of progressively or acutely failing beta cells, as is the case 
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in youths with either type 1 or type 2 diabetes. Therefore, the study of insulin sensitivity in 
youths with diabetes is limited by the inadequacy of current surrogate measures based on 
glucose and insulin levels [21]. In addition, such indices cannot be used in insulin-treated 
patients. In an effort to estimate insulin sensitivity non- invasively in adults with childhood-
onset type 1 diabetes from Pittsburgh, USA, a regression-based estimated glucose disposal 
rate score was developed and validated using the hyperinsulinaemic-euglycaemic clamp 
procedure in 24 adult patients with type 1 diabetes [22]. Using linear regression, the 
combination of risk factors that yielded the highest adjusted R2 value (0.57, p<0.001) was 
waist-hip ratio, hypertension and HbA1c [22]. We were not able to explore this score in our 
population as very few youths had hypertension. The only other such publication was from a 
study of 202 youths aged 8–18 years with type 1 diabetes in Poland [23]. In this study, 
clinical factors only explained 34% of the variance in GDR. Consistent with our findings, 
the prediction equation included waist circumference, triacylglycerols and HbA1c (in 
addition to Tanner stage and insulin dose). Our study is unique in that it included youths 
with type 1 and type 2 diabetes, and it controlled for diet and physical activity. In addition, 
we used a higher insulin dose than the Polish study, which was more likely to adequately 
suppress hepatic glucose output in pubertal adolescents [24].
In our study, 60% of the variance in GDR was explained by waist circumference alone. As 
expected, both body weight and BMI were strongly correlated with GDR univariately; 
however, the model selected waist circumference, a marker of total abdominal fat [25], as a 
main determinant of insulin sensitivity. This is consistent with data from non-diabetic 
normal-weight children, where percentage body fat was found to account for 55% of the 
variance in insulin sensitivity [26]. In a more recent study of multi-ethnic non-diabetic 
youths, waist circumference was the most significant correlate of insulin sensitivity, 
independent of race [27]. Elevated triacylglycerol level is a key abnormality in patients in 
insulin-resistant states, and is independently associated with the development of coronary 
heart disease [28]. In our model, triacylglycerol levels explained only 4.9% of the remaining 
variance in estimated insulin sensitivity, possibly marking more specifically the contribution 
of metabolically active visceral fat [29]. Similarly, HbA1c also had a small, although 
detectable, effect on estimated insulin sensitivity (8.2% of remaining variance), possibly 
reflecting the contribution of chronic hyperglycaemia to hepatic glucose output [30]. We 
found no interaction between clinical diabetes type and waist circumference or 
triacylglycerol and HbA1c levels on estimated insulin sensitivity, suggesting that the 
relationship between these predictors and insulin sensitivity is similar across the phenotypic 
spectrum of diabetes.
When using the IS score to model the relationship between residual insulin secretion and 
insulin sensitivity in the setting of a large epidemiological study of childhood diabetes, we 
found no relationship among those lacking substantial insulin secretory capacity (i.e. fasting 
C-peptide <0.14 nmol/l); however, an inverse relationship was noted among participants 
with preserved insulin secretion (r=−0.56, p<0.0001). This observation has important 
implications for the use of fasting C-peptide as a marker of insulin sensitivity for clinical or 
research purposes. First, it provides evidence that fasting C-peptide levels cannot be used as 
a surrogate marker of insulin resistance in individuals with severely compromised beta cell 
function. Second, in individuals with preserved beta cell function, there is an inverse 
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association between fasting C-peptide and estimated insulin sensitivity, without clear 
evidence of a threshold for insulin resistance. Importantly, these associations seem to be 
qualitatively similar regardless of DA status, although their magnitude is influenced by the 
different distribution of fasting C-peptide levels according to DA status: higher fasting C-
peptide levels in DA-negative vs DA-positive participants.
There are several limitations to our study. First, the clamp study included a convenience 
(non-random) sample. However, it included the three most prevalent racial/ethnic groups 
represented in SEARCH (non-Hispanic white, Hispanic and African-American) and a 
similar range of diabetes-related characteristics, including obesity, pubertal stage, C-peptide 
levels and antibody positivity, among others. The size of the sample with clamp 
measurements is relatively small. However, our study included the largest available sample 
of youths with type 1 diabetes (n=60) and one of the largest of youths with type 2 diabetes 
(n=25). Previous studies aimed at developing an index of insulin sensitivity in adults with 
type 1 diabetes were based on 24 participants [22]. Due to the relative rarity of the condition, 
other clinical studies including clamp measurements in youths with type 2 diabetes were 
based on 16–26 participants [31]. Nevertheless, additional validation of the proposed 
equation in other cohorts of youth with diabetes is warranted. In addition, due to the 
invasiveness of the clamp measurement, we were not able to include pre-pubertal children. 
Therefore, the IS score must be used with caution in pre-pubertal children.
An additional limitation is that hepatic glucose production was not measured as use of 
tracers and longer clamp protocols was not feasible in youths. Therefore, we cannot quantify 
the contribution of hepatic insulin sensitivity to overall insulin sensitivity measured in this 
study. Nonetheless, good glucose control and use of a high dose of insulin infusion to 
suppress hepatic glucose production probably minimised potential differences among study 
participants resulting from acute effects of hyperglycaemia on insulin sensitivity [24, 32]. 
Our protocol stopped the use of metformin for 3 days prior to the clamp. As metformin is 
known to improve insulin sensitivity [33], use of the equation in youths taking metformin 
may somewhat underestimate their degree of insulin sensitivity, though the primary factors 
used to predict insulin sensitivity (waist circumference, TG, HbA1c) are not acutely 
influenced by metformin. Only factors that were measured on the entire SEARCH cohort 
were considered for the development of the IS score and, thus, it is possible that a better 
estimate can be developed if additional factors are included. Finally, it is possible that 
different combinations of factors can be identified to more optimally predict insulin 
sensitivity in antibody-positive vs antibody-negative, obese vs lean or insulin-treated vs not-
insulin-treated youths with diabetes. However, the purpose of this study was to develop an 
estimate of insulin sensitivity that could be used reliably across the entire phenotypic 
spectrum of diabetes, rather than only in a selected subgroup of the population. We believe 
that this equation adequately meets this purpose, and is quite consistent with results from 
similar studies [22, 23, 26, 27]. Nonetheless, the generalisability of results from a selected 
subset to the entire population that it is intended to represent will always be an 
approximation. Because the range of diabetes characteristics included in this study is similar 
to that in the entire population, we believe that much of the inherent variability across the 
entire SEARCH population has been represented. Thus, we believe that our approach 
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captures the most relevant physiological relationships that can be useful as markers of 
insulin sensitivity in larger epidemiological studies.
In conclusion, our study provides evidence that insulin sensitivity can be estimated in 
adolescents with diabetes using routinely collected clinical measures. The score was used in 
a large epidemiological study to model the association between residual insulin secretion 
and insulin sensitivity. The score can be applied to large populations of youths with diabetes 
to more rigorously characterise relationships between various dimensions of diabetes type.
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Relationship between measured GDR and estimated IS score in (a) youths with diabetes 
(n=32), r=0.65, p<0.0001 (grey diamonds, type 1 diabetes; black squares, type 2 diabetes); 
(b) youths without diabetes (n=22), r=0.62, p=0.002 (black circles)
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Relationship between fasting C-peptide (FCP, nmol/l) and estimated IS score among all 
SEARCH participants (n=2,417): two-piece orthogonal regression splines. y1=−0.541x
+4.309, y2=−0.00132x+0.151 with a knot at x=7.7 (IS score), y=0.14 (FCP in nmol/l)
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Relationship between fasting C-peptide and insulin sensitivity by DA status among 
SEARCH participants: smooth spline averages. DA-positive: black (n = 1,780). DA-
negative: grey (n=610)
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Table 1
Demographic and clinical characteristics of youths with and without diabetes who had a clamp measurement
Characteristic Type 1 diabetes (n=60) Type 2 diabetes (n=25) p value Controls (n=22)
Current age (years)   15.4 (2.2)   15.7 (2.4)   0.66   15.0 (2.0)
Sex (% male)   43   30   0.29   50
Race (% NHW)   85   25 <0.0001   68
Tanner stage     4.3 (0.9)     4.7 (0.7)   0.11     4.5 (0.7)
BMI (kg/m2)   22.6 (4.7)   34.3 (6.7) <0.0001   26.7 (6.9)
Waist (cm)   76.0 (11.9) 107.9 (16.0) <0.0001   86.6 (16.3)
HbA1c (%)     8.6 (1.5)     7.8 (2.2)   0.07     5.0 (0.3)
Fasting glucose (mmol/l)     7.75 (2.48)     6.76 (2.07)   0.13     4.60 (0.32)
TG (mmol/l)a     0.85 (0.57)     1.63 (1.31) <0.0001     1.20 (1.35)
LDL-C (mmol/l)     2.17 (0.66)     2.38 (0.61)   0.16     2.22 (0.66)
HDL-C (mmol/l)     1.20 (0.25)     1.11 (0.30)     0.22     1.11 (0.24)
SBP (mmHg) 114.9 (12.2) 121.4 (11.5)     0.03 115.5 (8.5)
FCP (nmol/l)a     0.033 (0.033)     1.165 (0.965) <0.0001     0.799 (0.366)
ACR (μg/mmol)a     0.72 (0.9)     1.28 (3.9)   0.052     2.28 (0.7)
Treated with insulin (%) 100   20 <0.0001
GDR (mg kg−1 min−1)     8.5 (3.3)     4.3 (2.2) <0.0001   11.1 (5.1)
Data are expressed as percentages for categorical variables; means (standard deviations) for normally distributed variables
a
Medians (interquartile ranges) for skewed variables, where interquartile range represents the difference between the 75th and 25th percentile 
distribution p values for comparison of youths with type 1 diabetes vs youths with type 2 diabetes: χ 2 tests for categorical variables; t tests for 
normally distributed continuous variables; analysis of variance on log-transformed variables (for continuous variables that were not normally 
distributed) ACR, albumin:creatinine ratio; FCP, fasting C-peptide; NHW, non-Hispanic white; SBP, systolic blood pressure
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